SLC9C1 and neoplasm: Whilst 17.58% of tumour samples carry at least one ABT-SLC mutation (Fig. 1b), few tumours are able to carry multiple somatic mutations affecting the same sub-group of ABT-SLC (i.e. MCT, NHE, NBC, or AE).